STOCK TITAN
  1. Home
  2. News
  3. INDP

Indaptus Therapeutics Inc - INDP STOCK NEWS

Welcome to our dedicated news page for Indaptus Therapeutics (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Indaptus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Indaptus Therapeutics's position in the market.

News
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Rhea-AI Summary
Indaptus Therapeutics, Inc. unveils the positive results of its Decoy platform at the 2024 AACR Annual Meeting, showcasing the platform's ability to boost the immune system's response against tumors directly and indirectly. The study demonstrates the platform's effectiveness in activating various immune cell types involved in anti-tumor responses, potentially overcoming immune suppression mechanisms. The findings support the company's ongoing Phase 1 clinical trial of Decoy20 in solid tumors, indicating promising therapeutic potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
none
-
News
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) CEO to present at MedInvest Biotech & Pharma Investor Conference on April 3, 2024. The company focuses on pioneering cancer and viral infection treatments through innovative therapies leveraging the immune system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.04%
Tags
conferences
-
News
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) presents new data at the AACR annual meeting showcasing the effectiveness of its Decoy platform in activating multiple immune cell types involved in anti-tumor responses. Dr. Michael Newman highlights the ability of Decoy bacteria to induce M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells, leading to human tumor cell killing without significant toxicity. CEO Jeffrey Meckler expresses excitement over the potential of the Decoy platform in treating solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
none
News
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) announces CEO Jeffrey Meckler's participation in a webinar focusing on engaging the human immune system to cure diseases. The event is set for March 20, 2024, and registration is open on Tribe Public's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
conferences
-
News
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) announces positive results from the second cohort of the Phase 1 trial of Decoy20 for solid tumors, initiating multi-dosing. Key highlights include broad immune response in patients, approval of a key patent by the European Patent Office, and financial updates for the fourth quarter and fiscal year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
earnings
-
News
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) announces positive results from the second cohort of its Phase 1 INDP-D101 trial for Decoy20, leading to the recommendation to initiate multi-dosing. Patients exhibit a broad immune response, paving the way for potential anti-tumor activity across multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.92%
Tags
clinical trial
News
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) will present a corporate update at the 2024 BIO CEO & Investor Conference on February 26, 2024. The company focuses on developing innovative cancer and viral infection treatments leveraging the body's immune system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
-
News
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
Rhea-AI Summary
Indaptus Therapeutics, Inc. (INDP) has announced the launch of a new social media initiative to provide education and updates. The company is focused on pioneering innovative cancer and viral infection treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
Rhea-AI Summary
Indaptus Therapeutics, a clinical stage biopharma company (Nasdaq: INDP), has been granted a European patent by the EPO for a composition targeting viral infections, including hepatitis B, HIV, and influenza. The patent covers the company’s Decoy technology platform, providing protections for the prevention and treatment of any viral infection. This is the second patent granted to Indaptus outside the United States for this application. The CEO, Jeffrey Meckler, emphasized the competitive advantage and shareholder value this patent will bring, as the company continues to explore the applications of its technology platform beyond solid tumors and is currently engaged in a Phase 1 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
News
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Indaptus Therapeutics, Inc. announced financial results for Q3 2023, reporting encouraging early results from the INDP-D101 trial for the treatment of solid tumors. All four first cohort patients maintained stable disease and showed evidence of immune activation. The second cohort has already been dosed at a lower dose. The company appointed Roger Waltzman, M.D. as Chief Medical Officer. Financially, research and development expenses increased, while loss per share also increased. As of September 30, 2023, the company had approximately $16.0 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.07%
Tags
earnings
Stock INDP logo
Indaptus Therapeutics Inc

Nasdaq:INDP

INDP Rankings

#5093 Ranked by Market Cap
#1126 Ranked by Stock Gains
N/A Ranked by Dividends

INDP Stock Data

23.65M
5.90M
30.87%
7.05%
1.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
New York

About INDP

the indaptus goal is simple: to cure disease with the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.